SCHEMBL10150389

SCHEMBL10150389

C[C@H]1/C=C/CC/C=C/C(=O)Cc2c(Cl)c(O)cc(O)c2C(=O)O[C@@H]1C

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 4/20 0.71
MAPT P10636 3/20 0.54
HSP90AA1 P07900 2/20 0.54
GAA P10253 1/20 0.54
RAB9A P51151 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
NLRP3 Q96P20 1/20 0.54
CBR1 P16152 1/20 0.54
PTGS2 P35354 1/20 0.54
ACLY P53396 1/20 0.54
FTO Q9C0B1 1/20 0.54
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
HPGD P15428 1/20 0.54
KMT2A Q03164 1/20 0.54
F13A1 P00488 1/20 0.45
TGM2 P21980 1/20 0.45
STAT6 P42226 9/20 0.43
SMAD3 P84022 9/20 0.43
SMAD2 Q15796 9/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19418072 0.91 HSP90AB1 (0.60) HSP90AB1MAPTHSP90AA1GAARAB9A
Pochonin D SCHEMBL2683506 0.83 HSP90AB1 (1.00) HSP90AB1MAPTHSP90AA1GAARAB9A
Pochonin D SCHEMBL4513578 0.83 HSP90AB1 (1.00) HSP90AB1MAPTHSP90AA1GAARAB9A
SCHEMBL10150388 0.83 HSP90AB1 (0.49) HSP90AB1MAPTHSP90AA1GAARAB9A
Pochonin D SCHEMBL10150436 0.83 HSP90AB1 (1.00) HSP90AB1MAPTHSP90AA1GAARAB9A
Pochonin D SCHEMBL2683508 0.83 HSP90AB1 (1.00) HSP90AB1MAPTHSP90AA1GAARAB9A
Pochonin D SCHEMBL669590 0.83 HSP90AB1 (1.00) HSP90AB1MAPTHSP90AA1GAARAB9A
SCHEMBL10186737 0.80 HSP90AB1 (0.47) HSP90AB1MAPTHSP90AA1GAARAB9A
SCHEMBL19418283 0.79 HSP90AB1 (0.73) HSP90AB1MAPTHSP90AA1GAARAB9A
SCHEMBL10150393 0.79 HSP90AB1 (0.47) HSP90AB1MAPTHSP90AA1GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2136799-B1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 UNIV STRASBOURG (FR) 2017-10-04 EP disclosed
US-8450305-B2 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2013-05-28 US disclosed
US-8450305-B2 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2013-05-28 US disclosed
US-8329683-B2 Treatment of neurofibromatosis with radicicol and its derivatives NEXGENIX PHARMACEUTICALS, LLC (US) 2012-12-11 US disclosed
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-03-29 US disclosed
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-03-29 US disclosed
US-8067412-B2 analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen UNIVERSITE DE STRASBOURG (FR) 2011-11-29 US disclosed
US-8067412-B2 analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen UNIVERSITE DE STRASBOURG (FR) 2011-11-29 US disclosed
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives NEXGENIX PHARMACEUTICALS HOLDINGS, INC. 2010-11-18 US disclosed
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives NEXGENIX PHARMACEUTICALS HOLDINGS, INC. 2010-11-18 US disclosed
WO-2008150302-A1 TREATMENT OF NEUROFIBROMATOSIS WITH RADICICOL AND ITS DERIVATIVES NEXGENIX PHARMACEUTICALS (US) 2008-12-11 WO disclosed
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2008-06-19 US disclosed
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2008-06-19 US disclosed
WO-2008021213-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 WINSSINGER NICOLAS (FR) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 HSP90AB1, HSP90AA1, HSP90AB2P HSP90AB1 1/4885MAPT 1982/4885HSP90AA1 2/4885
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives HSP90AB2P, HSP90AA1, HSPA2 HSP90AB1 4/4885MAPT 2339/4885HSP90AA1 2/4885
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 HSP90AB1, HSP90AA1, HSP90AB2P HSP90AB1 1/4885MAPT 1982/4885HSP90AA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.